163 related articles for article (PubMed ID: 33504322)
1. Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer.
Couto RD; Fernandes BJD
Curr Drug Res Rev; 2021; 13(2):86-89. PubMed ID: 33504322
[TBL] [Abstract][Full Text] [Related]
2. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
Wang R; Zhang Y; Shan F
Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
[TBL] [Abstract][Full Text] [Related]
3. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
4. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
Donahue RN; McLaughlin PJ; Zagon IS
Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
[TBL] [Abstract][Full Text] [Related]
5. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
[TBL] [Abstract][Full Text] [Related]
6. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
Immonen JA; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
[TBL] [Abstract][Full Text] [Related]
7. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
[TBL] [Abstract][Full Text] [Related]
8. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
Zagon IS; Donahue R; McLaughlin PJ
Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of DNA synthesis in mouse epidermis by topical imiquimod is dependent on opioid receptors.
McLaughlin PJ; Rogosnitzky M; Zagon IS
Exp Biol Med (Maywood); 2010 Nov; 235(11):1292-9. PubMed ID: 20975079
[TBL] [Abstract][Full Text] [Related]
10. Intermittent blockade of OGFr and treatment of autoimmune disorders.
Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Dec; 243(17-18):1323-1330. PubMed ID: 30541348
[TBL] [Abstract][Full Text] [Related]
11. Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
McLaughlin PJ; Sassani JW; Klocek MS; Zagon IS
Brain Res Bull; 2010 Feb; 81(2-3):236-47. PubMed ID: 19683562
[TBL] [Abstract][Full Text] [Related]
12. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
Ludwig MD; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the opioid growth factor receptor in human cancers alter receptor function.
Kren NP; Zagon IS; McLaughlin PJ
Int J Mol Med; 2015 Jul; 36(1):289-93. PubMed ID: 26005722
[TBL] [Abstract][Full Text] [Related]
14. Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo.
Liu N; Ma M; Qu N; Wang R; Chen H; Hu F; Gao S; Shan F
Int Immunopharmacol; 2020 Sep; 86():106718. PubMed ID: 32585612
[TBL] [Abstract][Full Text] [Related]
15. Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers.
Zagon IS; Donahue RN; McLaughlin PJ
Am J Physiol Regul Integr Comp Physiol; 2009 Oct; 297(4):R1154-61. PubMed ID: 19675283
[TBL] [Abstract][Full Text] [Related]
16. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy.
Qu N; Meng Y; Handley MK; Wang C; Shan F
Int Immunopharmacol; 2021 Jul; 96():107714. PubMed ID: 33989971
[TBL] [Abstract][Full Text] [Related]
17. Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.
Hammer LA; Waldner H; Zagon IS; McLaughlin PJ
Exp Biol Med (Maywood); 2016 Jan; 241(1):71-8. PubMed ID: 26202376
[TBL] [Abstract][Full Text] [Related]
18. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy.
Ciwun M; Tankiewicz-Kwedlo A; Pawlak D
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539570
[TBL] [Abstract][Full Text] [Related]
19. Duration of opioid receptor blockade determines biotherapeutic response.
McLaughlin PJ; Zagon IS
Biochem Pharmacol; 2015 Oct; 97(3):236-46. PubMed ID: 26119823
[TBL] [Abstract][Full Text] [Related]
20. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.
Donahue RN; McLaughlin PJ; Zagon IS
Am J Physiol Regul Integr Comp Physiol; 2009 Jun; 296(6):R1716-25. PubMed ID: 19297547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]